Novel chemical solutions

built for licensing.

Soluda Labs identifies real-world problems and develops chemistry-based intellectual property to solve them, for licensing to companies that bring it to market.

From chemistry to commercial opportunity

Each program starts with a real-world problem. At its core is an original formulation and the method to make it, developed through iterative lab work and covered by our patent applications. That invention is what we license. Around it, we build what a licensee needs to evaluate and adopt it with confidence: our own test methods and data. A licensee takes it to market through scale-up, regulatory approval, production, and sales. Our model is license fees and royalties, with optional paid consulting for licensees.

Formulation equipment on a laboratory bench.

Development and patent status

DoneOngoingNot started

Bio-Concordant Personal Lubricant

  1. Problem definition

    Status: Done
  2. Research

    From late 2025

    Status: Done
  3. Bench testing and development Ongoing

    Since March 2026. Final test protocols under way.

    Status: Ongoing
  4. IP protection Ongoing

    Patent pending; U.S. provisional application filed January 2026; nonprovisional in preparation

    Status: Ongoing
  5. Partner and commercial path

    Open to licensing.

    Status: Not started

Vision Impairment Spray (VISPR)

  1. Problem definition

    Status: Done
  2. Research

    From November 2024

    Status: Done
  3. Bench testing and development Ongoing

    Since June 2025

    Status: Ongoing
  4. IP protection Ongoing

    Patent pending; U.S. nonprovisional utility application filed January 2026

    Status: Ongoing
  5. Partner and commercial path

    Open to licensing.

    Status: Not started

The founding team

For licensees

Tell us about your interests and what you would like to explore. We’ll follow up to arrange an introductory discussion about your priorities and potential fit.

For experts

Soluda works with outside specialists on defined technical questions, alongside our advisors. If your expertise is in formulation chemistry, regulatory affairs, or commercialization, we’d welcome a conversation.

Get in touch

For investors

Seth Halpern leads investor relations.

Email SethBook a call